文献速递呼吸道感染慢阻肺

铜绿假单胞菌社区获得性肺炎的全球负担与危险因素:住院患者多国点患病率研究

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients.
PubMed 文献 · Eur Respir J · 2018-08-09

该多国点患病率研究纳入54个国家3193例确诊社区获得性肺炎(CAP)且入院时接受微生物学检测的住院患者,评估铜绿假单胞菌CAP的患病率及危险因素。结果显示铜绿假单胞菌CAP患病率为4.2%,耐药铜绿假单胞菌CAP为2.0%。有既往铜绿假单胞菌感染/定植且合并特定慢性肺病者患病率达67%,而无上述因素者仅2%。

要点

  • 铜绿假单胞菌CAP全球患病率较低,为4.2%,耐药株为2.0%。
  • 既往铜绿假单胞菌感染/定植合并特定慢性肺病者患病率高达67%。
  • 无既往感染/定植且无特定慢性肺病者患病率仅2%,可指导经验性抗生素覆盖决策。

核心结论

  • 铜绿假单胞菌CAP的多国患病率较低,为4.2%,耐药铜绿假单胞菌CAP为2.0%。
  • 研究识别的危险因素可指导医疗专业人员决定CAP患者的经验性抗生素覆盖。

研究设计与样本

  • 多国点患病率研究,纳入54个国家3193例确诊CAP且入院时接受微生物学检测的住院患者。
  • 采用逻辑回归分析识别抗生素敏感和抗生素耐药铜绿假单胞菌CAP的危险因素。

主要发现

  • 铜绿假单胞菌CAP患病率为4.2%,抗生素耐药铜绿假单胞菌CAP患病率为2.0%。
  • 有既往铜绿假单胞菌感染/定植且合并至少一种三种独立相关慢性肺病(气管切开、支气管扩张和/或极重度慢阻肺)的患者,铜绿假单胞菌CAP发生率为67%。
  • 无既往铜绿假单胞菌感染/定植且无上述所选慢性肺病的患者,铜绿假单胞菌CAP发生率为2%。

关键数值与推荐

  • 铜绿假单胞菌CAP患病率4.2%,抗生素耐药铜绿假单胞菌CAP患病率2.0%。
  • 既往铜绿假单胞菌感染/定植合并气管切开、支气管扩张和/或极重度慢阻肺者铜绿假单胞菌CAP发生率为67%。
  • 无既往铜绿假单胞菌感染/定植且无上述慢性肺病者铜绿假单胞菌CAP发生率为2%。

临床怎么用

  • 对CAP患者决定经验性抗生素覆盖时,可参考既往铜绿假单胞菌感染/定植及特定慢性肺病(气管切开、支气管扩张、极重度慢阻肺)等危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP.We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP.The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases.The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Restrepo MI, Babu BL, Reyes LF, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Eur Respir J. 2018. PMID: 29976651. doi:10.1183/13993003.01190-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。